Advanced searches left 3/3

Dermatitis - Europe PMC

Summarized by Plex Scholar
Last Updated: 23 July 2022

* If you want to update the article please login/register

An explorative study comparing skin surface lipids in the West Highland white terrier dog with and without atopic dermatitis.

Skin surface lipids have been largely ignored, but they can also contribute to barrier function. An untargeted strategy was used to compare the skin lipids from atopic and non-atopic West Highland White terrier dogs. The secondary hypothesis was that affected and unaffected skin lipids could differ. Results Samples for lipid analysis revealed 421 lipid soluble features of which ten lipids were positively identified, according to lipid soluble results. A scientific study could not establish a correlation between non-atopic and atopic dogs, but did report a statistically significant difference in the lipid profiles from affected and non-affected skin, regardless of disease status. Conclusions A large number of unidentified lipids from the skin surface were discovered with a difference between affected and unaffected skin unrelated to disease status. The skin surface's lipidome study is a new area of research with both scientific and therapeutic uses.

Source link: https://europepmc.org/article/MED/35019832


Comparison of sensitization pattern to dust mite allergens between atopic dermatitis patients and dogs and non-specific reactivity of canine IgE to storage mite, Tyrophagus putrescentiae

Both in humans and dogs, house dust mite is a common cause of atopic dermatitis. The detection of serum IgE to allergen is often used to diagnose allergic disorders. We compared human and canine IgE reactivities to mite component allergens in human and canine IgE reactivities to mite component allergens. By tandem mass spectrometry, Canine IgE-reactive components of D. farinae and T. putrescentiae were identified in D. farinae and T. putrescentiae. The majority of patients were exposed to Der f 1 and Der f 2, and Der f 2 was a patient who was newly exposed. To Der f 2 and Der f 18, Dogs showed heightened sensitivity to Der f 2 and Der f 18. Both patients and dogs had low IgE binding frequency to Tyr p 8, 43. 3%, and 4% respectively, with 47%. The ELISA inhibition research showed that canine IgE reactivity to T. putrescentiae was mostly due to non-specific reaction and cross-reaction with D. farinae. The first time, allergic human and dogs with AD were shown with distinct IgE sensitization patterns, particularly to Der f 18 in Korea.

Source link: https://europepmc.org/article/PPR/PPR521440


Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review.

Atopic dermatitis is a chronic skin disease that has a significant effect on patient quality of life. By comparing terminology used in social media and scientific literature, unmet needs and AD disease burden were determined. AD terminology in social media was discovered using the NetBase platform, and natural language processing was carried out. More than three million social media mentions have been shared, and 1519 scientific journals were evaluated. The negative tone in relation to AD symptoms was mainly driven by face and hands, according to social media. Sleep and pain were often discussed together. In the same way, pruritus was the most common AD symptom co-occurring with QoL terms in the reviewed scientific literature. The patient experience of AD is provided by social media studies, providing a unique insight into the patient experience of AD. Symptoms that motivate negative emotion in social media seem to be discordantly represented in scientific literature. Incorporating patient perspectives can aid in disease detection and management.

Source link: https://europepmc.org/article/MED/35857381


Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.

At Week 16, the key endpoints of Investigator's Global Assessment score of 0/1 and 75% improvement in Eczema Area and Severity Index, as well as all confirmatory endpoints were much greater tralokinumab-treated patients, which included both confirmatory endpoints. Regardless of the response achieved at Week 16, this post hoc review investigated the effect of tralokinumab plus TCS on atopic dermatitis severity, symptoms, and health-related quality of life over the full 32-week treatment period of ECZTRA 3, including all patients initiated on etherokinumab, including all patients started on thalokinumab. Patients with a phenotypy of tralokinumab were randomized 1:1 to tralokinumab q2w or every 4 weeks for another 16 weeks at Week 16, with TCS as required. Patients not meeting the clinical response indicators with tralokinumab also received a w plus TCS from Week 16. Week 32, with 70% of patients achieving EASI-75 and 50. 4 at Week 42. Patients started on tralokinumab q2w plus TCS at Week 32 and reported a modest improvement relative to the baseline of 78% in the eczema-related sleep interference numeric rating scale and a 66. 8% in Dermatology Life Quality Index. At Week 16, the majority of patients started on tralokinumab q2w plus TCS showed a significant improvement in at least one of the three disease domains, including AD signs, symptoms, and QoL. At Week 16, 34% of patients started on tralokinumab q2w plus TCS, 53. 4% saw a clinically significant improvement in all three domains.

Source link: https://europepmc.org/article/MED/35857179


Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study

From a total of 42,000 patients with at least two AD diagnosis diagnoses: treated AD [mild to moderate and severe], and untreated or on drugs not included in the treated AD group were selected from two cohorts based on therapeutic status as the eligibility criteria were determined. The moderate-to-severe treated cohort was the highest for the moderate-to-severe treated cohort, followed by the mild-to-moderate treated cohort, and the lowest for the untreated cohort; patients with AD with any infection, asthma, or allergic rhinitis showed a similar pattern. However, the moderately treated AD cohort and the moderate-to-severe treated AD cohort had the highest mean HCRU cost among the mild-to-moderate treated AD cohort, followed by the moderate-to-severe treated AD cohort. Conclusions This research showed AD to be a common skin disease with a prevalence rate of 4u20135% in Dubai, with the majority of patients being seen by specialists.

Source link: https://europepmc.org/article/MED/PMC9294752


Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicenter retrospective cohort in daily practice.

Background Dupilumab is the first biotherapy approved for the treatment of moderate-to-severe childhood atopic dermatitis. Patients aged 6 to 11, who had received the first dose of dupilumab, were included in this multicenter retrospective cohort study. The change in IGA's score at 3 months, the percentage of patients with SCORAD50 and SCORAD75, a summary of adverse events, and the percentage of children in our study who will be excluded from pivotal phase 3 clinical trials were among the secondary endpoints. Since it was a real life study based on patient medical records in a French multicenter cohort, we cannot rule out the presence of reporting bias based on patient demographic characteristics and missing data. Conclusion These real-life data support the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, as well as a lower incidence of DFR and conjunctivitis.

Source link: https://europepmc.org/article/MED/35854650


Efficacy of Pseudo-Ceramide-Containing Steroid Lamellar Cream in Patients with Mild to Moderate Atopic Dermatitis: A Randomized, Double-Blind Study.

Introduction Atopic dermatitis is a chronic skin disease that results in reduced stratum corneum barrier function. For two weeks, the product or control cream was applied twice a day to a lesional area of 34 people with mild to moderate AD symptoms. The test cream's anti-inflammatory results were similar to those of the control cream in the double-blind experiment. At weeks 1 and 2 after application, a significant rise in the stratum corneum moisture content and a dramatic decrease in transepidermal water loss were observed in the test cream group, as compared to those before application. Conclusions Even with a short application period of 2 weeks, the test cream not only reduced inflammation of the lesional region but also increased the stratum corneum's inherent barrier function, indicating its use as a treatment option for patients with AD.

Source link: https://europepmc.org/article/MED/35852694


Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study.

Patients with at least two AD diagnosis were selected from a pool of patients with at least two AD diagnosis (mild to moderate and severe ) and untreated or on drugs not included in the treated AD cohort were chosen from a database of patients based on health status as the eligibility criteria were met. Mean annual disease-specific HCRU cost per patient was the highest for the moderate-to-severe treated cohort, followed by the mild-to-moderate treated cohort, and the lowest for the untreated cohort; patients with AD with no infection, asthma, or allergic rhinitis showed a similar pattern. The highest mean HCRU cost among the mild-to-moderate treated AD cohort was found among the mild-to-moderate treated AD cohort, followed by the moderately to severe treated AD cohort. Conclusion This research found AD to be a common skin disease with a prevalence rate of 4-5% in Dubai, with the majority of patients being seen by specialists.

Source link: https://europepmc.org/article/MED/35851651


Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.

ECZTEND, a nonprofit body that promotes healthcare, trials participants from previous tralokinumab parent trials with moderate to severe AD, evaluates tralokinumab plus optional topical corticosteroids in participants from previous terokinumab parent trials with moderate-to-severe AD. In a post hoc interim study, the aim is to determine the safety and effectiveness of up to two years of tralokinumab therapy. Adult participants treated with tralokinumab in ECZTEND for u22651 years were included in effectiveness studies, as well as subgroup analyses of those on tralokinumab for two years. In the safety investigation investigation, participants on tralokinumab had an exposure-adjusted rate of 237. 8 AEs/100 patient-years exposure in the safety analysis set.

Source link: https://europepmc.org/article/MED/35863467

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions